Our results indicated that a high level of OTUD1 drives JNK pathway activation, suggesting that OTUD1 might serve as a biomarker for JNK inhibition-based OCSC-targeted therapy. This evidence concerns the gene MAPK8 and oral cavity squamous cell carcinoma.